Recent studies have also demonstrated that co-administration of potentiators with complementary mechanisms of action may be an interesting approach for those CF-causing mutations in which CFTR gating/conductance is not completely restored by single potentiators (Phuan et al., 2018; Veit et al., 2019). The gene discussed is CFTR; the disease is cystic fibrosis.